Carlos Fernandez-Patron

Selected Publications:

1. Matrix metalloproteinase-2 negatively regulates cardiac secreted phospholipase a2 to modulate inflammation and fever .
   Berry E, Hernandez-Anzaldo S, Ghomashchi F, Lehner R, Murakami M, Gelb MH, Kassiri Z, Wang X, Fernandez-Patron C.
   J Am Heart Assoc. (2015) 4(4).
2. Emergence of a metalloproteinase / phospholipase a2 axis of systemic inflammation .
   Fernandez-Patron C, Leung D.
   Metalloproteinases Med. (2015) 2:29-38.
3. Identification of a novel heart/liver axis: Matrix metalloproteinases-2 negatively regulates cardiac secreted phospholipase a2 to modulate lipid metabolism and inflammation in the liver.
   Hernandez-Anzaldo S, Berry E, Brglez V, Leung D, Yun TJ, Lee JS, Filep JG, Kassiri Z, Cheong C, Lambeau G, Lehner R, Fernandez-Patron C.
   J Am Heart Assoc. (2015) Nov 13;4(11).

1. Reverse staining of sodium dodecyl sulfate polyacrylamide gels by imidazole-zinc salts: Sensitive detection of unmodified proteins.
   Fernandez-Patron C, Castellanos-Serra L, Rodriguez P.
   Biotechniques. (1992) 12:564-573.
2. Understanding the mechanism of the zinc-ion stains of biomacromolecules in electrophoresis gels: Generalization of the reverse-staining technique .
   Fernandez-Patron C, Castellanos-Serra L, Hardy E, Guerra M, Estevez E, Mehl E, Frank RW.
   Electrophoresis. 1998;19:2398-2406.

1. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor.
   Fernandez-Patron C, Radomski MW, Davidge ST.
   Circ Res. (1999)85:906-911.
2. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction .
   Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST.
   Circ Res. (2000) 87:670-676.
3. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway .
   Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C.
   Circ Res. (2004) 94:68-76.
4. Matrix metalloproteinase-7 and adam-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy.
   Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S, Cooper S, Odenbach J, Finegan BA, Schulz R, Kassiri Z, Lopaschuk GD, Fernandez-Patron C.
   Circulation. 2009;119:2480-2489.
5. Metalloproteinases in hypertension and cardiac disease: Differential expression and mutual regulation.
   Bosonea AM, Wang X, Odenbach J, Fernandez-Patron C.
   Drug Discov Today Dis Models. (2011) 8:29-35.
6. Gpcrs in cardiovascular pathologies.
   Fernandez-Patron C, Filep JG.
   Drug Discov Today Dis Mech. (2012) 9:e75-e78.
7. Metalloproteinases: Key and common mediators of multiple gpcrs and candidate therapeutic targets in models of hypertensive cardiac disease.
   Wang X, Bosonea AM, Fernandez-Patron C.
   Drug Discov Today Dis Models. 2012;9:e103-e108.
8. Identification of a novel heart/liver axis: Matrix metalloproteinases-2 negatively regulates cardiac secreted phospholipase a2 to modulate lipid metabolism and inflammation in the liver.
   Hernandez-Anzaldo S, Berry E, Brglez V, Leung D, Yun TJ, Lee JS, Filep JG, Kassiri Z, Cheong C, Lambeau G, Lehner R, Fernandez-Patron C.
   J Am Heart Assoc. (2015) Nov 13;4(11).